Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ocrelizumab Impairs the Phenotype and Function of Memory CD8+ T Cells: A 1-Year Longitudinal Study in Patients With Multiple Sclerosis.

Neurology(R) neuroimmunology & neuroinflammation - 1 Mar 2023

Mathias Amandine, Pantazou Vasiliki, Perriot Sylvain, Canales Mathieu, Jones Samuel, Oberholster Larise, Moulin Michaël, Fenwick Craig, Bernard-Valnet Raphaël, Théaudin Marie, Pot Caroline, Du Pasquier Renaud A

Abstract excerpt

BACKGROUND AND OBJECTIVE: Depleting CD20+ B cells is the primary mechanism by which ocrelizumab (OCRE) is efficient in persons with multiple sclerosis (pwMS). However, the exact role of OCRE on other immune cell subsets directly or indirectly remains elusive. The purpose of this study is to characterize the dynamics of peripheral immune cells of pwMS on OCRE. METHODS: We collected blood samples from 38 pwMS...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD8-Positive T-Lymphocytes
Share to Epstein-Barr Virus Infections

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Herpesvirus 4, Human

Share to Longitudinal Studies

Share to Multiple Sclerosis

Share to Phenotype

Source

Open in PubMed Open full text

Identifiers

PMID: 36717268
DOI: 10.1212/NXI.0000000000200084
PMCID: PMC9887539

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ocrelizumab Impairs the Phenotype and Function of Memory CD8+ T Cells: A 1-Year Longitudinal Study in Patients With Multiple Sclerosis.PMID 36717268Read ↗

Effect of Cumulative Exposure to Ocrelizumab on Memory B‐Cell Repopulation Dynamics in Multiple SclerosisSemantic proximity Read ↗

B-Cell and T-Cell Populations in Peripheral Blood Linked to Ocrelizumab Treatment Efficacy in Multiple SclerosisSemantic proximity Read ↗

Differential effects of anti-CD20 therapy on CD4 and CD8 T cells and implication of CD20-expressing CD8 T cells in MS disease activitySemantic proximity Read ↗

Immune profiling of COVID-19 vaccine responses in people with multiple sclerosis on B cell-depleting therapySemantic proximity Read ↗

Memory B Cells in Multiple Sclerosis: Emerging Players in Disease Pathogenesis.Semantic proximity Read ↗

Deficiency of CD8 <sup>+</sup> effector memory T cells is an early and persistent feature of multiple sclerosisSemantic proximity Read ↗

B- and T cell receptor sequencing elucidates characteristics of lymphocyte depletion by ocrelizumabSemantic proximity Read ↗

Low memory T cells blood counts and high naïve regulatory T cells percentage at relapsing remitting multiple sclerosis diagnosisSemantic proximity Read ↗

Dynamics of spinal fluid immune cell alterations following cladribine tablet treatment in multiple sclerosisSemantic proximity Read ↗

CD19 Cell Count at Baseline Predicts B Cell Repopulation at 6 and 12 Months in Multiple Sclerosis Patients Treated with OcrelizumabSemantic proximity Read ↗

Immune dynamics in SARS-CoV-2 experienced immunosuppressed rheumatoid arthritis or multiple sclerosis patients vaccinated with mRNA-1273Semantic proximity Read ↗

Immune aging in multiple sclerosis is characterized by abnormal CD4 T cell activation and increased frequencies of cytotoxic CD4 T cells with advancing ageSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.